Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 6—June 2012

CME ACTIVITY

Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing Enterobacteriaceae and Infection after Liver Transplant, France

Frédéric BertComments to Author , Béatrice Larroque, Catherine Paugam-Burtz, Federica Dondero, François Durand, Estelle Marcon, Jacques Belghiti, Richard Moreau, and Marie-Hélène Nicolas-Chanoine
Author affiliations: Hôpital Beaujon, Clichy, France (F. Bert, B. Larroque, C. Paugam-Burtz, F. Dondero, F. Durand, E. Marcon, J. Belghiti, R. Moreau, M.H. Nicolas-Chanoine); Université Paris VII Faculté de Médecine D. Diderot, Paris, France (C. Paugam-Burtz, F. Durand, J. Belghiti, M.H. Nicolas-Chanoine); INSERM U 773 Centre de Recherche Biomédicale Bichat-Beaujon, CRB3, Paris (F. Durand, R. Moreau, M.H. Nicolas-Chanoine)

Main Article

Table 2

Temporal evolution of ESBLE pretransplant fecal carriage and posttransplant infection, France, by time period, January 2001–April 2010*

Variable No. (%) patients
p value†
2001–2003, n = 185 2004–2006, n = 196 2007–2008, n = 188 2009–2010, n = 141
Pretransplant ESBLE fecal carriage 0 5 (2.5) 9 (4.8) 15 (10.6) <0.0001
Posttransplant ESBLE infection 3 (1.6) 9 (4.6) 9 (4.8) 18 (12.8) <0.0001

*ESBLE, extended spectrum β-lactamase–producing Enterobacteriaceae.
†Comparison among the 4 periods by test of trend.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO